Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 37TH ANNUAL SLEEP 2023 MEETING

For Print (PDF)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO®), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.

Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea (poster numbers: #298, 299 and 300).

Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative products as soon as possible in therapeutic areas with high unmet medical needs, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

SLEEP 2023 Poster Presentations

Asset and Presentation Details (Time EDT) Title

Lemborexant
Poster #297
Monday, June 5, 12:00 – 13:15

Long-term Efficacy of Lemborexant on Objective Sleep Measures in Clinical Practice

Lemborexant
Poster #298
Monday, June 5, 17:00 – 18:00

Effect of Lemborexant on Sleep Architecture in Subjects with Comorbid Insomnia and Mild Obstructive Sleep Apnea from a Ph 3 Trial

Lemborexant
Poster #299
Monday, June 5, 12:00 – 13:15

The Effect of Lemborexant on Polysomnographic Sleep Parameters in Adults with Mild, Moderate, or Severe Obstructive Sleep Apnea

Lemborexant
Poster #300
Monday, June 5, 17:00 – 18:00

Effect of Lemborexant on Sleep Architecture in Adult and Elderly Subjects with Mild to Severe Obstructive Sleep Apnea

Lemborexant
Poster #301
Monday, June 5, 12:00 – 13:15

Shifts in Daytime Functioning Items on the Insomnia Severity Scale with Lemborexant after 6 Months of Treatment

Lemborexant
Poster #302
Monday, June 5, 17:00 – 18:00

Differential Effect of Lemborexant and Zolpidem on Wake Across the Night in Patients with Insomnia Disorder

Lemborexant
Poster #303
Monday, June 5, 12:00 – 13:15

Impact of Lemborexant on Daytime Ratings of Sleepiness/Alertness in Subjects with Insomnia Disorder and Baseline Sleepiness

Narcolepsy general
Poster #248
Monday, June 5, 17:00 – 18:00

Burden of Narcolepsy in Japan: A Nationwide Real-world Database Study from The Perspectives of Direct Medical Cost and Comorbidity

 

Media Inquiries
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
TEL: +551-305-0050
Christopher_Vancheri@eisai.com

[Notes to editors]
1. About Lemborexant (product name: DAYVIGO)
Lemborexant, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant’s potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan, the United States, Canada, Australia and countries in Asia.

Our Values

Values are an integral part of our foundation. With every decision, we ensure that we follow:

Integrity

Integrity is the living up to legal, moral and ethical principles in the conduct of HI-Eisai Pharmaceutical Inc. business. It means that each employee embodies the value of integrity, and therefore represents the company in honesty and rectitude in all the ways they do their work.

It is expected that each employee would make decisions guided by good judgement, not just for one‘s self, but for HI-Eisai as the company. An employee who acts with integrity ensures that he has understanding of the principles by which the company operates, and in situations where he lacks clarity, will actively seek guidance.

Respect

The company is committed to ensure that it maintains a safe, inclusive, and healthy working environment that promotes productivity among employees. All employees are expected to show respect to fellow employees, customers, and patients, regardless of differences in gender, culture, backgrounds, and beliefs. Leaders in the organization are likewise expected to promote inclusivity with their teams, and shall not tolerate any discriminatory and offensive actions.

Accountability

Accountability at work means assuming responsibility for the business outcome and how that is achieved. It means that every employee, in whichever position, are equally responsible for the decisions and actions they make for the company. It is likewise, the responsibility of each employee to report, any knowledge of misconduct or potential violation to the company‘s rules and regulations.

Patient-Centric

At the heart of the company‘s operation are the patients. This means that every decision to be made, considers the potential impact and benefit to the patients. As such, the company commits itself in ensuring that business objectives align with its principle of human health care or hhc. The programs created and implemented are based on how well they could contribute to improving patients‘ lives.

For field-based employees, being patient-centric means that the focus of engagements with customers are on understanding patient needs as well as providing these stakeholders with comprehensive information on how HI-Eisai‘s products can support their patients goals.

For each employee, being patient-centric means taking on their responsibilities with care and consideration on how it impacts the patients experience, be it by making relevant information readily available for the doctors; or by ensuring access and availability to the medicines we offer.

Excellence

As a patient-centric company, we define Excellence by the outstanding quality of our work to improve patients‘ lives. Each employee is expected to consistently demonstrate work ethics that align to our values, policies, and our desire to provide above standard service. The company is committed in ensuring that all actions are in compliance with legal requirements.

Being excellent means that every employee passionately strives to be better and participates in the company‘s initiatives to develop their members in terms of knowledge, skills, and behavior, which will support a continuously improving, responsible and performance-driven workforce.

Our Vision

To be a successful and sustainable business in the Philippines by driving innovation and providing solutions to address unmet healthcare needs fueled by high-performing employees who deliver meaningful value and experience to patients and their families.

Our Mission

We give first thought to patients and their families, and to increasing the benefits health care provides.

Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160